Lupin has received USFDA approval for its Dapagliflozin and Metformin extended-release tablets in multiple strengths, boosting its US diabetes portfolio. Shares of Lupin Ltd ended marginally lower on Wednesday, April 8, by 0.18% at ₹2,294.10 on the NSE.
